Table 1.
Baseline characteristics and treatment effect of all included patients
| Age, years; median (range) | 66 (24–89) |
| Observation period, days; median (range) | 100 (7–1514) |
| Sex | |
| Male | 78 (60%) |
| Female | 53 (40%) |
| Primary site | |
| Lungs | 35 (27%) |
| Genitourinary tract | 34 (26%) |
| Gastrointestinal tract | 34 (26%) |
| Breasts | 6 (5%) |
| Head and neck | 5 (4%) |
| Thyroid | 4 (3%) |
| Gynecology | 4 (3%) |
| Unknown | 9 (7%) |
| Histology | |
| Squamous cell carcinoma | 9 (7%) |
| Adenocarcinoma | 66 (50%) |
| Small cell carcinoma | 4 (3%) |
| Clear cell carcinoma | 22 (17%) |
| Others | 27 (21%) |
| Unknown | 3 (2%) |
| Imaging modality | |
| CT (including simulation CT) | 131 (100%) |
| MRI | 54 (41%) |
| Bone scintigraphy | 56 (43%) |
| 18FDG-PET | 14 (11%) |
| Metastatic site | |
| Vertebral | 86 (66%) |
| Non-vertebral | 45 (34%) |
| Bone metastases type | |
| Osteolytic | 88 (67%) |
| Osteoblastic | 34 (26%) |
| Mixed | 9 (7%) |
| Pathological fracture | |
| Present | 24 (18%) |
| Absent | 107 (82%) |
| Treatment effect | |
| Response | 105 (80%) |
| Non-response | 26 (20%) |
CT computed tomography, MRI magnetic resonance imaging, 18FDG-PET 18fluorodeoxyglucose-positron emission tomography